FLT3 and acute myeloid leukemia: Results of preclinical studies and early clinical trials have demonstrated that treatment with MIs, e.g., SNDX-50469, revumenib, and ziftomenib, effectively induce cell differentiation and loss of viability in the preclinical models and induce complete remissions in patients with AML with mtNPM1 with or without FLT3 mutation but not in AML without mtNPM1.